Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about SIGA, unsubscribe in one click. Privacy
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Tecovirimat (ST-246) FDA approved Jul 2018 · Tpoxx |
Smallpox | Phase 4 · NCT04485039 | Completed |
| Tecovirimat Monohydrate | Smallpox | Phase 4 · NCT04392739 | Completed |
| MVA-BN Smallpox Vaccine | Smallpox | Phase 2 · NCT04957485 | Active not recruiting |
| TPOXX IV (Tecovirimat Injection, 10 mg/mL) | Orthopox Virus Infection | N/A · NCT05380752 | No longer available |
Also used in these trials (approved or third-party drugs, not SIGA's own candidates): Calcium Acetate, Lanthanum Carbonate, Sevelamer Carbonate, Sucroferric Oxyhydroxide.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
SIGA holds $116.4M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when SIGA files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Daniel J Luckshire Executive VP & CFO · +55,228 options |
Insider | 280,493 | 0.39% | 2026-03-13 |
| Joseph W III Marshall Director · +34,169 options |
Insider | 246,523 | 0.34% | 2026-06-09 |
| Dennis E Hruby EVP & Chief Scientific Officer · +54,942 options |
Insider | 198,537 | 0.28% | 2026-03-13 |
| Diem Nguyen Chief Executive Officer, Director · +390,820 options |
Insider | 138,767 | 0.19% | 2026-03-13 |
| Jaymie A Durnan Director · +34,169 options |
Insider | 88,754 | 0.12% | 2026-06-09 |
| Holly L. Phillips Director · +34,169 options |
Insider | 73,754 | 0.10% | 2026-06-09 |
| Gary J. Nabel Director · +34,169 options |
Insider | 73,754 | 0.10% | 2026-06-09 |
| Julian Nemirovsky Director · +34,169 options |
Insider | 73,754 | 0.10% | 2026-06-09 |
| Larry R. Miller General Counsel · +20,762 options |
Insider | 51,912 | 0.07% | 2026-03-25 |
| Harold Eugene Jr. Ford Director · +34,169 options |
Insider | 47,538 | 0.07% | 2026-06-09 |
| Evan A. Knisely Director · +19,084 options |
Insider | 17,298 | 0.02% | 2024-06-11 |
| Jay Varma EVP & Chief Medical Officer, Director |
Insider | 17,298 | 0.02% | 2024-06-11 |
Share count 71,855,015 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SIGA and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →